Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

318 ARTÍCULOS , VIENDO DEL 1 AL 15

Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties

Papadopoulos V, Lecanu L.

J Neuroendocrinol. 2012 Jan;24(1):93-101. doi: 10.1111/j.1365-2826.2011.02167.x.

Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease

Haas C.

J Alzheimers Dis. 2012;28(2):241-81. doi: 10.3233/JAD-2011-110986.

Antioxidative strategies in cognitive impairment: a novel connection between biliverdin-reductase and statins

Schneider A, Simons M.

J Neurochem. 2012 Jan;120(1):1-3. doi: 10.1111/j.1471-4159.2011.07548.x.

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F.

Br J Clin Pharmacol. 2012 Apr;73(4):504-17. doi: 10.1111/j.1365-2125.2011.04134.x.

Tau-targeted treatment strategies in Alzheimer's disease

Götz J, Ittner A, Ittner LM.

Br J Pharmacol. 2012 Mar;165(5):1246-59. doi: 10.1111/j.1476-5381.2011.01713.x.

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease

Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER.

Clin Neuropharmacol. 2012 Jan-Feb;35(1):25-9. doi: 10.1097/WNF.0b013e31823a13d3.

Reviewing the role of donepezil in the treatment of Alzheimer's disease

Doody RS, Cummings JL, Farlow MR.

Curr Alzheimer Res. 2012 Sep;9(7):773-81. doi: 10.2174/156720512802455412.

Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease

Tobinick E.

Curr Alzheimer Res. 2012 Jan;9(1):99-109. doi: 10.2174/156720512799015073.

Health state values for use in the economic evaluation of treatments for Alzheimer's disease

Shearer J, Green C, Ritchie CW, Zajicek JP.

Drugs Aging. 2012 Jan 1;29(1):31-43. doi: 10.2165/11597380-000000000-00000.

Natural antioxidants in prevention and management of Alzheimer's disease

Zhao Y, Zhao B.

Front Biosci (Elite Ed). 2012 Jan 1;4(3):794-808. doi: 10.2741/419.

Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease

de la Monte SM.

Front Biosci (Elite Ed). 2012 Jan 1;4(4):1582-605. doi: 10.2741/e482.

[Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease]

Fujii A, Shinagawa R, Chatani Y, Toriyama K, Shirahase T, Suzuki K.

Nihon Yakurigaku Zasshi. 2012 Jan;139(1):26-32. doi: 10.1254/fpj.139.26.

Possibility of a new anti-alzheimer's disease pharmaceutical composition combining memantine and vitamin D

Annweiler C, Beauchet O.

Drugs Aging. 2012 Feb 1;29(2):81-91. doi: 10.2165/11597550-000000000-00000.

Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease

Molinuevo JL, Arranz FJ.

Expert Rev Neurother. 2012 Jan;12(1):31-7. doi: 10.1586/ern.11.178.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias